Pharmaron

Haixin zhihui is an artificial intelligence company. They offer intelligent diagnosis, and treatment systems for tumor diseases have been developed. They provide patients with precise treatment recommendations and assist patients in treatment planning and full disease management.

Shanghai Jiying uses intelligent technology, focusing on data analysis and AI algorithms.

Rxilient is a company that specializes in providing contract development and manufacturing organization (CDMO) services for the pharmaceutical sector. It manufactures and distributes a range of pharmaceutical products aimed at addressing unmet medical, health, and beauty needs. The company offers a comprehensive portfolio of dermatology and medical aesthetic products, developed with a scientific approach, to support its clients in meeting various requirements for skin health and aesthetics. Through its services, Rxilient aims to enhance the effectiveness and accessibility of health and beauty solutions in the market.

Allergan Biologics developing, manufacturing and commercializing branded pharmaceutical, device, biologic, surgical and regenerative medicine products.

Imago BioSciences is a clinical-stage biotechnology company based in Redwood City, California, that specializes in developing innovative medicines for hematologic diseases. Founded in 2012, the company focuses on therapeutics that target genetic and epigenetic factors, specifically through the inhibition of lysine-specific demethylase 1 (LSD1), an enzyme crucial in blood cell production. Imago BioSciences aims to address significant medical challenges associated with conditions such as leukemia, myelodysplastic syndrome, and other bone marrow disorders. Its lead product candidate, Bomedemstat, is an orally available small molecule designed to treat certain myeloproliferative neoplasms, with the goal of altering disease progression and improving the quality and longevity of patients' lives.

Absorption Systems develops and implements research tools that allow their customers to better predict human outcomes. They have locations in Exton, Pennsylvania, San Diego, California, and Panama City, Panama. They work with a wide variety of customers in the pharmaceutical and biotech industry, including small virtual pharma companies, large pharma companies with weekly programs, and specialty CROs looking for services that complement their own offerings. Their flexibility allows us to adapt to the needs of each customer. They believe that projects should be viewed as a collaboration, which allows us to work with you to design studies and develop custom models when necessary. This collaborative approach has resulted in the generation of several innovative models to aid in drug discovery and development, through working partnerships within the industry and with regulatory agencies.

Xceleron believes that AMS technology and our expertise can get life-changing products quickly and cost-effectively to people who need them. We work with integrity and an open mind and are driven by science and the spirit of collaboration. Founded in 1997 in York, UK, and now headquartered in Germantown, Maryland, Xceleron pioneered human microdose and microtracer techniques using AMS to investigate the pharmacokinetics and metabolism of developmental drugs in Phase 0, Phase I, and Phase II/III clinical trials. Xceleron’s experience is especially valuable because the characteristics of many contemporary small molecules (low solubility, long half-life and disproportionate human metabolites) mean that their early pharmacokinetic and metabolic characterization is critical to the cost-effectiveness of clinical development.

Quotient Bioresearch is a leading CRO, providing Radiochemistry, Drug Metabolism and E-fate solutions tailored, integrated.

Bridge Laboratories, Inc. operates as a preclinical contract research organization. Its drug development and preclinical services include short and long-term in vivo studies ranging from acute to carcinogenicity protocols; and species and routes of administration.